Impact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used Drugs

Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT

(2012) P Balasubramanian et al.   BONE MARROW TRANSPLANTATION

Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism

(2012) Y Liu et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers

(2012) Can-Jun Ruan et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers

(2012) Barbara Gawrońska-Szklarz et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics

(2011) Jung-woo Bae et al.   ACTA PHARMACOLOGICA SINICA

Effects of the CYP2C9*1/*13 Genotype on the Pharmacokinetics of Lornoxicam

(2011) Chang-Ik Choi et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Stereoselective pharmacokinetics of stable isotope (+/−)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity

(2011) David L. Thacker et al.   CHIRALITY

Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement

(2011) Dietmar Trenk et al.   Circulation-Cardiovascular Genetics

CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects

(2011) Chang-Ik Choi et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects

(2011) Hee-Doo Yoo et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype–phenotype correlation in childhood

(2011) Ersin Gumus et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP

(2011) Patricia Huezo-Diaz et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole

(2011) Imad Zalloum et al.   MOLECULAR BIOLOGY REPORTS

Pharmacogenomics of clopidogrel: Evidence and perspectives

(2011) Tong Yin et al.   THROMBOSIS RESEARCH

Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam

(2010) Jung-Woo Bae et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential Effect

(2010) G. L. Kearns et al.   DRUG METABOLISM AND DISPOSITION

Benzbromarone Pharmacokinetics and Pharmacodynamics in Différent Cytochrome P450 2C9 Genotypes

(2010) Shinya Uchida et al.   Drug Metabolism and Pharmacokinetics

Pharmacokinetic and Pharmacodynamic Variation Associated with VKORC1 and CYP2C9 Polymorphisms in Thai Patients Taking Warfarin

(2010) Alisara Sangviroon et al.   Drug Metabolism and Pharmacokinetics

Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole

(2010) Barbara Gawrońska-Szklarz et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers

(2010) H. Shao et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects

(2009) Jung-Woo Bae et al.   ARCHIVES OF PHARMACAL RESEARCH

Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 andABCB1

(2009) Hee-Doo Yoo et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

(2009) Alain Li-Wan-Po et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Substrate-Dependent Functional Alterations of Seven CYP2C9 Variants Found in Japanese Subjects

(2009) K. Maekawa et al.   DRUG METABOLISM AND DISPOSITION

The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects

(2009) Bo Tan et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram

(2009) Salvador Fudio et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure

(2009) Yuyan Jin et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

(2009) Eunice Yuen et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Rapid Identification of the Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive [13C]Pantoprazole Breath Test

(2009) Z. Desta et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Effects of genetic variation at theCYP2C19/CYP2C9locus on pharmacokinetics of chlorcycloguanil in adult Gambians

(2009) Ramatoulie E Janha et al.   PHARMACOGENOMICS

The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients

(2009) P W Schenk et al.   PHARMACOGENOMICS JOURNAL

Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes

(2009) M. Karaźniewicz-łada et al.   XENOBIOTICA

Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population

(2008) Katsuyoshi Sugimoto et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers

(2008) R. Michael Baldwin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Determinants of Steady-State Torasemide Pharmacokinetics

(2008) Dierk Werner et al.   CLINICAL PHARMACOKINETICS

Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9

(2008) C Sachse-Seeboth et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Differential Genotype Dependent Inhibition of CYP2C9 in Humans

(2008) V. Kumar et al.   DRUG METABOLISM AND DISPOSITION

Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients

(2008) I. Rudberg et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects

(2008) Staffan Ohlsson Rosenborg et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers

(2008) Guo Wang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

(2008) K. UMEMURA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Pharmacogenetic relevance of the CYP2C93 allele in a tenoxicam bioequivalence study performed on Spaniards

(2008) A PEIRO et al.   PHARMACOLOGICAL RESEARCH